Hainan Shuangcheng Pharmaceuticals Co., Ltd.

Shenzhen Stock Exchange 002693.SZ

Hainan Shuangcheng Pharmaceuticals Co., Ltd. Price to Book Ratio (P/B) on January 14, 2025: 13.74

Hainan Shuangcheng Pharmaceuticals Co., Ltd. Price to Book Ratio (P/B) is 13.74 on January 14, 2025, a 107.64% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Hainan Shuangcheng Pharmaceuticals Co., Ltd. 52-week high Price to Book Ratio (P/B) is 33.57 on October 29, 2024, which is 144.24% above the current Price to Book Ratio (P/B).
Hainan Shuangcheng Pharmaceuticals Co., Ltd. 52-week low Price to Book Ratio (P/B) is 3.79 on February 07, 2024, which is -72.39% below the current Price to Book Ratio (P/B).
Hainan Shuangcheng Pharmaceuticals Co., Ltd. average Price to Book Ratio (P/B) for the last 52 weeks is 9.75.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

Shenzhen Stock Exchange: 002693.SZ

Hainan Shuangcheng Pharmaceuticals Co., Ltd.

CEO	Mr. Jianming Li
IPO Date	Aug. 8, 2012
Location	China
Headquarters	No. 16 Xingguo Road
Employees	474
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Hainan Shuangcheng Pharmaceuticals Co., Ltd. researches, develops, manufactures, and markets synthesized peptide drugs and active pharmaceutical ingredients worldwide. It offers somatostatin, thymosin, clindamycin hydrochloride, thymopentin, L-carnitine, uranin hydrobromide, inosine, cyclophosphine adenosine, motidine, scopolamine, and sodium ferulate for injections, as well as vitamin B6. The company was founded in 2000 and is based in Haikou, the People's Republic of China.

Key trends

Past 5 years